KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biogen (BIIB) Equity Average (2016 - 2025)

Biogen (BIIB) has 15 years of Equity Average data on record, last reported at $8.8 billion in Q3 2025.

  • For Q3 2025, Equity Average changed N/A year-over-year to $8.8 billion; the TTM value through Sep 2025 reached $8.8 billion, changed N/A, while the annual FY2024 figure was $15.8 billion, 11.81% up from the prior year.
  • Equity Average reached $8.8 billion in Q3 2025 per BIIB's latest filing, down from $17.3 billion in the prior quarter.
  • Across five years, Equity Average topped out at $17.3 billion in Q2 2025 and bottomed at $8.8 billion in Q3 2025.
  • Average Equity Average over 5 years is $12.9 billion, with a median of $11.5 billion recorded in 2022.
  • Peak YoY movement for Equity Average: fell 17.49% in 2021, then rose 22.52% in 2023.
  • A 5-year view of Equity Average shows it stood at $10.9 billion in 2021, then rose by 5.69% to $11.5 billion in 2022, then grew by 22.37% to $14.1 billion in 2023, then grew by 10.11% to $15.6 billion in 2024, then plummeted by 43.36% to $8.8 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $8.8 billion in Q3 2025, $17.3 billion in Q2 2025, and $16.8 billion in Q1 2025.